Anti-CD20 (Rituximab), Chimeric Antibody

Anti-CD20 (Rituximab), Chimeric Antibodyis available at Gentaur for Next week Delivery.

Description: Rituximab, a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20. Mechanisms of cell destruction that have been demonstrated to be activated by rituximab binding to CD20 include direct signaling of apoptosis, complement activation and antibody dependent cellular cytotoxicity. Rituximab is a mainstay in the therapy for a broad variety of B-cell malignancies.

Immunogen Sequence:CD20

Target Alternative Name:MabThra

Species Reactivities:Human

Tag Line:Monoclonal human IgG1 antibody against human CD20

Formulation:100 ug (2 mg/ml) of antibody in Phosphate buffered saline, pH 7.4.

Purification: human IgG1 was expressed in a human cell line. IgG was purified from CHO cell culture supernatant by protein A chromatography.

Application:Neutralization, ELISA

Positive Control:/

Application And Usages:Activation : 1-20 μg/ml; ELISA: 2μg/ml

Handling:The antibody solution should be gently mixed before use